Imunovir™ (inosine pranobex) is an immunomodulator of the potentiator type which has demonstrated an enhancing effect on the function and number of various cells of the immune system, particularly T lymphocytes. Imunovir™ has the ability to enhance the functions of various cells within the immune system and it seems likely that these effects are responsible for its clinical efficacy. Therapy with an agent capable of enhancing certain aspects of the immune response is a logical approach to the treatment of disorders associated with an underlying cellular immune defect. These include viral diseases and immune deficiency states.

Imunovir™ is also known in different parts of the world as Isoprinosine®, Viruxan®, Prinosine® and Virimun®. It is approved outside of Canada for a variety of viral infections resulting from depression of the immune system. A partial list includes Aolpecia areata, CMV, EBV, Hepatitis acute and non-chirrotic chronic active B, Influenza, Measles Mumps, Viral conjunctivitis and subacute sclerosing panencephalitis (SSPE). A pilot study in Chronic Fatigue Syndrome has been published (see Abstract), but its use in this indication is still considered investigational. Imunovir™ is approved for the treatment of SSPE in Canada.

 View clinical study results.

Clinical improvement in chronic fatigue syndromeJournal of Chronic Fatigue Syndrome.Volume 11. Clinical improvement in chronic fatigue syndrome is associated with enhanced natural killer cell-mediated cytotoxicity: the results of a pilot study with Isoprinosine®

Center for Multidisciplinary Research on Chronic Fatigue Syndrome (CFS) & Gulf War Illness, University of Miami, and Miami Veterans Affairs Medical Center, Miami Florida. Immune and Viral Response to Isoprinosine in Chronic Fatigue Syndrome.

Imunovir™ is the trademark of Newport Pharmaceuticals Limited.